Mostrar o rexistro simple do ítem

dc.contributor.authorGarcía Fernández, Patricia*
dc.contributor.authorPóvoa Cabral, María Clara*
dc.contributor.authorBeceiro Casas, Alejandro*
dc.contributor.authorMoscoso Naya, Miriam*
dc.contributor.authorBou Arévalo, Germán *
dc.date.accessioned2025-09-08T12:22:49Z
dc.date.available2025-09-08T12:22:49Z
dc.date.issued2023
dc.identifier.citationGarcía P, Cabral MP, Beceiro A, Moscoso M, Bou G. Cross-Protection against Acute Staphylococcus aureus Lung Infection in Mice by a D-Glutamate Auxotrophic Vaccine Candidate. Vaccines. 2023;11(2).
dc.identifier.issn2076-393X
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/6416a5095db420433b7b62f3
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21294
dc.description.abstractStaphylococcus aureus is regarded as a threatening bacterial pathogen causing invasive pneumonia in healthcare settings and in the community. The continuous emergence of multidrug resistant strains is narrowing the treatment options for these infections. The development of an effective S. aureus vaccine is, therefore, a global priority. We have previously developed a vaccine candidate, 132 ?murI ?dat, which is auxotrophic for D-glutamate, and protects against sepsis caused by S. aureus. In the present study, we explored the potential of this vaccine candidate to prevent staphylococcal pneumonia, by using an acute lung infection model in BALB/c mice. Intranasal inoculation of the vaccine strain yielded transitory colonization of the lung tissue, stimulated production of relevant serum IgG and secretory IgA antibodies in the lung and distal vaginal mucosa and conferred cross-protection to acute pneumonia caused by clinically important S. aureus strains. Although these findings are promising, additional research is needed to minimize dose-dependent toxicity for safer intranasal immunization with this vaccine candidate.
dc.description.sponsorshipThis work was supported by a grant from the Servicio Galego de Saude (SERGAS)-Galician Healthcare Service (Programs Innova Saude), the Spanish Network for Research in Infectious Diseases (RD12/0015/0014 and RD16/0016/0006) and Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas (CIBERINFEC). The work was funded by Instituto Carlos III (ISCIII) through projects PI15/00860, PI18/00501 and PI21/00704 to GB; and PI20/01212 to AB, co-funded by European Regional Development Fund A way to make Europe; and by GAIN-Agencia Gallega de Innovacion-Conselleria de Economia, Emprego e Industria through the project IN607D 2021/12 to AB. PG was supported by the Spanish Network for Research in Infectious Diseases (RD12/0015/0014 and RD16/0016/0006). MPC was supported by a PhD scholarship (SFRH/BD/64740/2009) from Portugal and POPH/FSE.
dc.languageeng
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleCross-Protection against Acute Staphylococcus aureus Lung Infection in Mice by a D-Glutamate Auxotrophic Vaccine Candidate
dc.typeArtigo
dc.authorsophosGarcía, P.; Cabral, M.P.; Beceiro, A.; Moscoso, M.; Bou, G.
dc.identifier.doi10.3390/vaccines11020210
dc.identifier.sophos6416a5095db420433b7b62f3
dc.issue.number2
dc.journal.titleVaccines*
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario A Coruña::Unidade de investigación
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Biomédica de A Coruña (INIBIC)
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario A Coruña::Microbioloxía
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario A Coruña::Unidade de investigación
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario A Coruña::Microbioloxía
dc.relation.projectIDServicio Galego de Saude (SERGAS)-Galician Healthcare Service (Programs Innova Saude)
dc.relation.projectIDSpanish Network for Research in Infectious Diseases [RD12/0015/0014, RD16/0016/0006]
dc.relation.projectIDCentro de Investigacion Biomedica en Red de Enfermedades Infecciosas (CIBERINFEC)
dc.relation.projectIDInstituto Carlos III (ISCIII) [PI15/00860, PI18/00501, PI21/00704, PI20/01212]
dc.relation.projectIDEuropean Regional Development Fund A way to make Europe
dc.relation.projectIDGAIN-Agencia Gallega de Innovacion-Conselleria de Economia, Emprego e Industria [IN607D 2021/12]
dc.relation.projectIDPortugal and POPH/FSE [SFRH/BD/64740/2009]
dc.relation.publisherversionhttps://doi.org/10.3390/vaccines11020210
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS A Coruña
dc.subject.keywordCHUAC
dc.subject.keywordAS A Coruña
dc.subject.keywordINIBIC
dc.subject.keywordAS A Coruña
dc.subject.keywordCHUAC
dc.subject.keywordAS A Coruña
dc.subject.keywordCHUAC
dc.subject.keywordAS A Coruña
dc.subject.keywordCHUAC
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number11


Ficheiros no ítem

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Attribution 4.0 International (CC BY 4.0)
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAttribution 4.0 International (CC BY 4.0)